What is Biohaven Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Biohaven's interest expense for the
three
months ended in Dec. 2023 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Biohaven's Operating Income for the
three
months ended in Dec. 2023 was $ -153.71 Mil. Biohaven's Interest Expense for the
three
months ended in Dec. 2023 was $ 0.00 Mil.
GuruFocus does not calculate Biohaven's interest coverage with the available data.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Biohaven Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biohaven (NYSE:BHVN) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Biohaven's Interest Expense for the
three
months ended in Dec. 2023 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Dec. 2023 was $-153.71 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2023 was $27.57 Mil.
Biohaven's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
| GuruFocus does not calculate Biohaven's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Biohaven Ltd has enough cash to cover all of its debt. Its financial situation is stable.
Biohaven (Biohaven) Business Description
Traded in Other Exchanges
N/A
Address
215 Church Street, New Haven, CT, USA, 06510
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on discovering and developing therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, immunology, and disease-related biology, including rare disorders. Its neuroscience portfolio includes a broad pipeline of drug candidates modulating distinct nervous system targets, including Kv7, glutamate receptors, myostatin, and TRP channels. Its products target diseases such as migraine, depression, bipolar, and schizophrenia.
Executives
| Irina Antonijevic |
director |
215 CHURCH STREET, NEW HAVEN CT 06510 |
| John W Childs |
director |
111 HUNTINGTON AVENUE, SUITE 2900, BOSTON MA 02199 |
| Vlad Coric |
director, officer: Chief Executive Officer |
C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510 |
| Matthew Buten |
officer: Chief Financial Officer |
215 CHURCH STREET, NEW HAVEN CT 06510 |
| Gregory Bailey |
director |
4 A CHESHAM STREET, LONDON X0 SW1X8DT |
| George C. Clark |
officer: VP, Chief Accounting Officer |
215 CHURCH STREET, NEW HAVEN CT 06510 |
| Julia P Gregory |
director |
8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381 |
| Robert J Hugin |
director |
C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054 |
| Michael Thomas Heffernan |
director |
C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518 |
| Kimberly Gentile |
officer: SVP, Clinical Operations |
C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510 |
| Kishan Mehta |
director |
540 WEST 49TH STREET, UNIT# PH1N, NEW YORK NY 10019 |
| Biohaven Pharmaceutical Holding Co Ltd. |
10 percent owner |
215 CHURCH STREET, NEW HAVEN CT 06510 |
| Bruce Car |
officer: Chief Scientific Officer |
AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139 |
Biohaven (Biohaven) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BHVN has been successfully added to your 